Artivion (NYSE:AORT) Posts Earnings Results, Beats Estimates By $0.03 EPS

Artivion (NYSE:AORT) issued its quarterly earnings data on Thursday. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03, FiscalAI reports. The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.

Artivion Trading Up 1.5%

AORT traded up $0.61 during trading on Thursday, hitting $40.71. 779,657 shares of the company’s stock were exchanged, compared to its average volume of 328,191. Artivion has a 1 year low of $21.97 and a 1 year high of $48.25. The stock has a 50 day moving average price of $43.86 and a 200 day moving average price of $42.77. The firm has a market cap of $1.93 billion, a P/E ratio of -169.63 and a beta of 1.59. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Canaccord Genuity Group reiterated a “buy” rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $49.11.

Insider Buying and Selling at Artivion

In related news, CEO James P. Mackin sold 30,921 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares in the company, valued at approximately $36,493,241.08. This trade represents a 3.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John E. Davis sold 6,394 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $45.17, for a total value of $288,816.98. Following the completion of the transaction, the insider owned 198,842 shares of the company’s stock, valued at approximately $8,981,693.14. This represents a 3.12% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 141,234 shares of company stock worth $6,366,621. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter worth approximately $27,000. Smartleaf Asset Management LLC increased its holdings in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the period. Quadrant Capital Group LLC acquired a new position in Artivion during the 3rd quarter valued at about $92,000. iSAM Funds UK Ltd acquired a new position in Artivion during the 3rd quarter valued at about $131,000. Finally, Van ECK Associates Corp grew its position in Artivion by 19.0% in the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock worth $134,000 after purchasing an additional 506 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.